What are unclassified cardiomyopathies?

Unclassified cardiomyopathies include all those that do not fall into the four conventional categories and encompass rare or difficult-to-classify forms such as Takotsubo, non-compaction (LVNC), mitochondrial, autoimmune, toxic, fibrinous, and idiopathic cardiomyopathies.

What are the main causes of unclassified cardiomyopathies?

Causes include physical/emotional stress (Takotsubo), genetic mutations, storage diseases, autoimmunity, exposure to toxic substances or drugs, and inflammatory processes.

How is an unclassified cardiomyopathy diagnosed?

Diagnosis requires echocardiogram, cardiac MRI, genetic testing, muscle/cardiac biopsy, and often coronary angiography to rule out ischemia.

What are the most frequent complications?

Heart failure, ventricular arrhythmias, systemic embolism, and, in some cases, sudden cardiac death.

What are the therapeutic options?

Treatment depends on the form: diuretics, beta-blockers, ACE inhibitors, anticoagulants, immunosuppressants for autoimmune forms, implantable defibrillator, and in selected cases, heart transplantation.

L'angolo del dottorino

Change Language:

Index

Search the site... Advanced search

✖

Unclassified Cardiomyopathies

Article written and reviewed by Dr Luca Moretti

Unclassified cardiomyopathies are a heterogeneous group of cardiac disorders that do not fit into the four main categories of cardiomyopathies (dilated, hypertrophic, restrictive, and arrhythmogenic).
These conditions present with atypical morphological and functional features and may have genetic, metabolic, or toxic causes.

Depending on the specific form, the main pathophysiological mechanisms include:

Neurohormonal dysfunction: typical of Takotsubo cardiomyopathy, in which catecholamine excess induces abnormal myocardial contractility.
Genetic alterations: responsible for non-compaction and mitochondrial cardiomyopathy, affecting myocardial structure and function.
Pathological storage: metabolic and storage diseases (Fabry, hemochromatosis) cause infiltration of substances into the myocardium, impairing its function.
Toxic factors: certain drugs and toxins can induce direct myocardial injury or alterations in cellular metabolism.

Below is a brief overview of all unclassified cardiomyopathies and their key features.

Takotsubo Cardiomyopathy

Definition and Pathogenesis

Also known as "broken heart syndrome," this is a transient cardiomyopathy often triggered by severe emotional or physical stress. It is characterized by acute left ventricular dysfunction with apical hypokinesia and basal hyperkinesia.

Clinical Features

The main symptoms mimic acute myocardial infarction:

Chest pain
Dyspnea
ECG abnormalities (ST-segment elevation, inverted T waves)
Moderately elevated troponin

Diagnosis

Echocardiography and cardiac MRI show the classic "takotsubo" (Japanese octopus pot) morphology. Coronary angiography excludes significant coronary stenosis.

Treatment

Supportive therapy with beta-blockers and ACE inhibitors. Recovery generally occurs within 4-8 weeks.

Left Ventricular Non-Compaction (LVNC)

Definition and Pathogenesis

LVNC is characterized by abnormal myocardial compaction during fetal development, with prominent trabeculations and deep recesses. It is associated with mutations in sarcomeric genes (MYH7, ACTC1).

Clinical Features

Patients may present with:

Progressive heart failure
Ventricular arrhythmias
Thromboembolic events

Diagnosis

Contrast echocardiography and cardiac MRI allow visualization of hypertrophic trabeculations and intertrabecular recesses.

Treatment

Includes therapy for heart failure and anticoagulants in patients at thrombotic risk.

Mitochondrial Cardiomyopathies

Definition and Pathogenesis

These are due to mutations in mitochondrial genes that impair cardiac energy production. They may present with early heart failure and systemic myopathies.

Clinical Features

Patients may present with:

Chronic fatigue
Associated skeletal myopathy
Progressive dilated cardiomyopathy

Diagnosis

Muscle biopsy and genetic analysis confirm the diagnosis.

Treatment

No specific therapy is available; treatment is aimed at optimizing cardiac function with ACE inhibitors and beta-blockers.

Hypereosinophilic Cardiomyopathy

Toxic Cardiomyopathies

Definition and Pathogenesis

These result from exposure to cardiotoxic drugs (anthracyclines, cocaine, alcohol) causing direct injury to cardiomyocytes.

Clinical Features

They present with symptoms of heart failure and arrhythmias.

Diagnosis

Cardiac MRI shows areas of myocardial fibrosis.

Treatment

Withdrawal of the toxic agent and heart failure management.

Idiopathic Restrictive Cardiomyopathy

Definition and Pathogenesis

This is a rare form of cardiomyopathy characterized by abnormal myocardial stiffness without evident causes such as infiltration or storage. Ventricular filling is impaired, resulting in diastolic heart failure.

Clinical Features

Dyspnea on exertion and at rest
Peripheral edema
Asthenia
Atrial arrhythmias (atrial fibrillation)

Diagnosis

Echocardiography: non-dilated ventricles with reduced compliance.
Cardiac catheterization: elevated filling pressures.
Cardiac MRI: can exclude infiltrative causes (amyloidosis, sarcoidosis).

Treatment

There is no specific therapy. Diuretics are used to reduce congestion and rhythm control medications as needed. In advanced cases, heart transplantation may be considered.

Cardiac functional alterations and clinical manifestations are similar to those of restrictive cardiomyopathy, of which it can be considered a subset with no identifiable cause, and the diagnosis is made by exclusion.

Endomyocardial Fibrinous Cardiomyopathy

Definition and Pathogenesis

A rare disorder characterized by progressive endomyocardial fibrosis, leading to restrictive ventricular filling and intracavitary thrombosis.

Clinical Features

Signs of right heart failure
Systemic embolism
Exercise intolerance

Diagnosis

Echocardiography reveals fibrotic endocardial thickening and thrombi. MRI can confirm the diagnosis.

Treatment

Therapy includes anticoagulants, diuretics, and, in selected cases, surgical resection of fibrotic tissue.

Danon Disease

Definition and Pathogenesis

A lysosomal storage disease linked to the X chromosome, caused by mutations in the LAMP2 gene. It leads to severe hypertrophic cardiomyopathy with progressive dysfunction.

Clinical Features

Hypertrophic cardiomyopathy with progressive heart failure
Skeletal myopathy
Ventricular arrhythmias and conduction blocks
Cognitive deficits (in the most severe cases)

Diagnosis

Cardiac biopsy: evidence of lysosomal accumulation.
Genetic testing: identification of LAMP2 mutation.

Treatment

Heart transplantation may be required in advanced cases. Supportive treatment for heart failure and arrhythmias.

Cardiomyopathies Secondary to Neuromuscular Disorders

Definition and Pathogenesis

Some neuromuscular diseases, such as Duchenne and Becker muscular dystrophies, cause progressive cardiomyopathies due to dystrophin deficiency, resulting in myocardial degeneration.

Clinical Features

Progressive heart failure
Ventricular arrhythmias
Reduced exercise capacity

Diagnosis

Echocardiography and cardiac MRI show progressive myocardial dilatation and fibrosis.

Treatment

Treatment is based on beta-blockers, ACE inhibitors, and implantable defibrillators for patients at risk of malignant arrhythmias.

Cardiomyopathies Due to Autoimmune Diseases

Definition and Pathogenesis

Autoimmune diseases such as scleroderma, systemic lupus erythematosus, and inflammatory myopathies may affect the myocardium, leading to chronic inflammation and fibrosis.

Clinical Features

Dyspnea and fatigue
Arrhythmias and conduction blocks
Associated pericarditis

Diagnosis

Echocardiography: myocardial thickening and contractile dysfunction.
Cardiac MRI: evidence of fibrosis.
Autoantibodies: ANA, anti-SSA, anti-Scl-70.

Treatment

Corticosteroids and immunosuppressants may improve cardiac function. Heart failure treatment is standard.

References

Maron BJ et al. Contemporary Definitions and Classification of Cardiomyopathies. Circulation. 2006;113(14):1807-1816.
Elliott P et al. Classification of Cardiomyopathies: A Position Statement. Eur Heart J. 2008;29(2):270-276.
Finsterer J. Primary Myopathies and the Heart. Scand Cardiovasc J. 2008;42(1):9-24.
Lyon AR et al. Takotsubo Syndrome: Aetiology, Presentation and Treatment. Heart. 2016;102(18):1461-1469.
Oechslin EN, Jenni R. Left Ventricular Non-Compaction Revisited. Eur Heart J. 2011;32(12):1446-1456.
Kühl U et al. Viral Persistence in Myocardium and Progressive Dysfunction. Circulation. 2005;112(13):1965-1970.
Ghadri JR et al. Long-Term Prognosis of Takotsubo Syndrome. J Am Coll Cardiol. 2018;72(8):874-882.
Packer M et al. Neurohormonal Antagonism in Heart Failure. Circulation. 1999;100(5):549-557.
Basso C et al. Arrhythmogenic Cardiomyopathy: A Disease of Cardiac Stem Cells? Circulation. 2012;125(4):635-648.
Pinto YM et al. Revised Definition of Dilated Cardiomyopathy. Eur Heart J. 2016;37(23):1850-1858.